Extension of ST Ultrasonography · people with ST of the leg
Fondaparinux probably leads to lower extension of ST Ultrasonography compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence of ST Ultrasonography · people with ST of the leg
Fondaparinux probably leads to lower recurrence of ST Ultrasonography compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with ST of the leg
Fondaparinux showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Minor bleeding · people with ST of the leg
Fondaparinux showed no clear difference in minor bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects of treatment · people with ST of the leg
Fondaparinux showed no clear difference in adverse effects of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people with ST of the leg
Prophylactic LMWH showed no clear difference in symptomatic VTE compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people with ST of the leg
1 finding from 1 review
Occurrence of leg ulceration · patients with PTS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in PTS · patients with PTS
Rutosides showed no clear difference in improvement in PTS (8 weeks ‐ 12 months) compared with placebo (or no treatment) (low certainty).
1 finding from 1 review
Deterioration in PTS · patients with PTS
Rutosides showed no clear difference in deterioration in PTS (8 weeks ‐ 12 months) compared with placebo (or no treatment) (low certainty).
1 finding from 1 review
Adverse effects (8 weeks ‐ 12 months) · patients with PTS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · people with critical limb ischaemia
Prostanoids showed no clear difference in cardiovascular mortality compared with placebo (low certainty).
1 finding from 1 review
Amputation · people with critical limb ischaemia
Prostanoids showed no clear difference in total amputations compared with placebo (high certainty).
1 finding from 1 review
Quality of life · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events (participants) · people with critical limb ischaemia
Prostanoids probably leads to higher adverse events (participants) compared with placebo (moderate certainty).
1 finding from 1 review
Rest‐pain relief · people with critical limb ischaemia
Prostanoids probably leads to higher rest‐pain relief (dichotomous) compared with placebo (moderate certainty).
1 finding from 1 review
Ulcer healing · people with critical limb ischaemia
Prostanoids probably leads to higher ulcer healing compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
5 participants
GRADE not reported